Cascadia Medical Equipment, a Seattle-based company, has unveiled a new roma-powered medical device that it claims can treat injuries and diseases that are caused by bacteria.
The new device, called the roma, can produce an immune response, or immune response that can be triggered by bacteria, in the body.
Cascadia says the device can treat a wide range of conditions including:The roma is currently only available in two sizes: the 10-ounce (2.5-kilogram) container and the 10.25-ounce container.
The 10-inch container can be bought for about $1,200 (AU$1,800) and the 25-ounce can cost $3,200.
The company says the roms are available for purchase online and in retail stores, and that they are designed for patients who need the latest in biotechnology and technology, but are not yet certified for use in hospitals.
Cesar C. Sanchez, CEO of Cascada, told Reuters the company plans to launch a second line of roma devices, but this time it will include a medical device device, an oxygen delivery system, and an emergency response system.
The romano, or the Roman alphabet, is the first written word in Latin, and the language is a mixture of Latin and Greek.
The word roman is a common suffix used to mean “many” or “great”, and it was also used to indicate an enormous number, as in a billion or a million.
A roma has the same physical characteristics as a regular container of medicines.
It can hold up to three times the volume of medicine or can be carried in the mouth for a few minutes before being drained.
It is usually sold for about one cent a dose.
The device uses a new form of technology called “biotechnologies” that have been developed in a lab, which use bacteria to deliver an immune reaction.
Capsules of bacteria are used to deliver the immune response.
A doctor could use a capsule to deliver a medication to a patient, but Cascadian says the capsules have a higher safety profile.
The capsules can be used by patients as an alternative to medication for infections or conditions like asthma, or to treat injuries that have not yet been treated.
Caleb Fong, a biomedical engineer at the University of Washington, said the technology has the potential to be a major breakthrough in the treatment of a range of diseases, including diabetes and Crohn’s disease.
“The use of bacteria for medical devices, even though it’s not a new technology, has been a big breakthrough for the last 20 years or so,” he told Reuters.
“We think it’s a significant step forward and a major advancement in the field of medicine.”
The company, which has raised $5.7 million in a Series B round, is working with the U.S. Food and Drug Administration (FDA) to develop the device.
“I am very excited about the opportunity to work with the FDA, the CDC, and others on this project,” Fong said.
“These innovations are important in the fight against infectious diseases and could have a huge impact on the way the world thinks about medicine in the future.”
Cascada’s new device is designed to help treat conditions that are triggered by infection, such as viral infections, bacterial infections and bacterial diseases such as HIV.
Fong said the company’s research was focused on using bacteria to generate a more effective immune response to these infections.
“Our work on the romanos was about designing an immune system that could deliver the proper immune response,” he said.
“We’re looking at ways to deliver this response to infections that have caused damage to the mucosa or the tissue that the infection spreads through.”
The FDA has approved a prototype for use on humans in hospitals, but it is not yet available to use on the public.